Enterprise Value
-37.43M
Cash
258.9M
Avg Qtr Burn
-36.5M
Short % of Float
17.45%
Insider Ownership
3.18%
Institutional Own.
92.75%
Qtr Updated
08/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NX-1607 Details Solid tumor/s, Cancer | Phase 1 Data readout | |
NX-2127 (BTK degrader) Details Non-Hodgkin lymphoma, Blood cancer, Cancer, B-cell malignancies, Chronic lymphocytic leukemia, Mantle cell lymphoma, Diffuse large B cell lymphoma | Phase 1 Data readout | |
NX-5948 Details Cancer, B-cell malignancies | Phase 1 Data readout | |
NX-1607 + paclitaxel Details Solid tumor/s, Cancer | Phase 1a Data readout | |
DeTIL-0255 Details Ovarian cancer, Cancer, Cervical cancer, Endometrial cancer | Failed Discontinued |